Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20564397 | 1.00 | SLC6A5 (0.38) | SLC6A5EPHX2DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL403391 | 1.00 | SLC6A5 (0.38) | SLC6A5EPHX2DPP7MEN1FAAH | |
| SCHEMBL3975666 | 0.99 | EPHX2 (0.39) | SLC6A5EPHX2DPP7MEN1FAAH | |
| SCHEMBL3975670 | 0.99 | EPHX2 (0.39) | SLC6A5EPHX2DPP7MEN1FAAH | |
| SCHEMBL30130875 | 0.99 | EPHX2 (0.39) | SLC6A5EPHX2DPP7MEN1FAAH | |
| SCHEMBL25364547 | 0.99 | EPHX2 (0.39) | SLC6A5EPHX2DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL3486209 | 0.94 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL27908684 | 0.94 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL27686644 | 0.94 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL446666 | 0.94 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038557-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SILENCE THERAPEUTICS GMBH (DE) | 2019-02-07 | — | — | US | claimed |
| EP-1771206-B1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2018-04-11 | — | — | EP | claimed |
| US-20170296469-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS GMBH (DE) | 2017-10-19 | — | — | US | claimed |
| US-9486538-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2016-11-08 | — | — | US | claimed |
| US-20160303047-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SILENCE THERAPEUTICS GMBH (DE) | 2016-10-20 | — | — | US | claimed |
| EP-3076950-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | Silence Therapeutics GmbH (DE) | 2016-10-12 | — | — | EP | claimed |
| US-9387262-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2016-07-12 | — | — | US | claimed |
| WO-2016083624-A1 | MEANS FOR INHIBITING THE EXPRESSION OF EDN1 | SILENCE THERAPEUTICS GMBH (DE) | 2016-06-02 | — | — | WO | claimed |
| WO-2016083623-A1 | MEANS FOR THE TREATMENT OF PRE-ECLAMPSIA | SILENCE THERAPEUTICS GMBH (DE) | 2016-06-02 | — | — | WO | claimed |
| EP-2992902-A1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USES | Silence Therapeutics GmbH (DE) | 2016-03-09 | — | — | EP | claimed |
| JP-2007536324-A | — | — | 2007-12-13 | — | — | JP | claimed |
| WO-2007121946-A2 | MEANS FOR INHIBITING THE EXPRESSION OF CD31 | SILENCE THERAPEUTICS AG (DE) | 2007-11-01 | — | — | WO | claimed |
| WO-2007121947-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS AG. (DE) | 2007-11-01 | — | — | WO | claimed |
| EP-1830888-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | Silence Therapeutics AG (DE) | 2007-09-12 | — | — | EP | claimed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2006069782-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG. (DE) | 2006-07-06 | — | — | WO | claimed |
| EP-1638580-A2 | USE OF DOUBLE-STRANDED RIBONUCLEIC ACID FOR INDUCING CELL LYSIS | atugen AG (DE) | 2006-03-29 | — | — | EP | claimed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | claimed |
| US-20050043263-A1 | Use of double-stranded ribonucleic acid for inducing cell lysis | ATUGEN AG (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2005000320-A2 | USE OF DOUBLE-STRANDED RIBONUCLEIC ACID FOR INDUCING CELL LYSIS | ATUGEN AG (DE) | 2005-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043263-A1 | Use of double-stranded ribonucleic acid for inducing cell lysis | RNASE1, RNASEH1, RNASEL | RRM1 66/4885SLC6A5 3962/4885EPHX2 3947/4885 |
| US-20160303047-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SGMS1, SGMS2, DEGS1 | RRM1 1049/4885SLC6A5 2900/4885EPHX2 1272/4885 |
| US-20170296469-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | LIPG, LIPA, PHOSPHO1 | RRM1 2016/4885SLC6A5 529/4885EPHX2 191/4885 |
| US-20190038557-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SGMS1, SGMS2, DEGS1 | RRM1 1049/4885SLC6A5 2900/4885EPHX2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.